Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
1
self-reported band not used
Founded
2019
7 years
Legal entities
1
ABR
Office countries
2
2 addresses
Funding rounds
1
Post IPO equity · Jun 2020 · US$ 26.0M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
INVEX THERAPEUTICS LTD
ABN29632145334
Legal entities
Show as table · Invex Therapeutics: 1 registry entity
| INVEX THERAPEUTICS LTD | ABN 29632145334 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Invex Therapeutics (ASX: IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™.
Locations
2
Countries with an office address2 addresses on record
AustraliaprimaryUnited Kingdom
Country footprint
Show as table · Offices in 2 countries
| Countries | 2 |
|---|---|
| Primary country | AU |
All codes: AU GB
Addresses
- AU38 Rowland Street; Level 1; Subiaco, WA 6008Primary
- GBUnit 28, Birmingham Research Park; 97 Vincent Drive; Edgbaston, B15 2SQ
Grid intelligence Members
Funding
Last round · 22 June 2020US$ 26.0MPost IPO equity
Rounds1
Round typePost IPO equity · secondary transaction
Amount (USD)26,000,000
Stage rank6
Investors named0
Since last round5 yr 6 mo
Funding
Show as table · 1 funding round
| Rounds | 1 |
|---|---|
| Axis | 2019 to 2026 |
| Post IPO equity · 22 Jun 2020 | US$ 26.0M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
FAQ
Which legal entity operates under Invex Therapeutics?
One Western Australia entity on the ABR: INVEX THERAPEUTICS LTD (ABN 29 632 145 334), high confidence.
How many people work at Invex Therapeutics?
1 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does Invex Therapeutics have offices?
Two addresses on record across 2 countries. Primary: 38 Rowland Street, Level 1, Subiaco, WA 6008.
Has Invex Therapeutics raised funding?
One round. Latest 22 June 2020: post IPO equity, US$26,000,000.
Which companies are listed alongside Invex Therapeutics?
3 profiles list Invex Therapeutics as a peer — 49th percentile in Biotechnology Research. It lists ten peers of its own. Neurotech International Ltd and Incite Genomics list it back.